Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMG 910

Next Previous
Search
Drug Profile

AMG 910

Alternative Names: AMG-910; CLDN18.2 HLE BiTE®

Latest Information Update: 29 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; BeiGene
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastric cancer; Oesophageal cancer

Most Recent Events

  • 29 Nov 2022 Discontinued - Phase-I for Gastric cancer (In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in Taiwan, Netherlands, South Korea, Japan, Germany, France, Austria (Parenteral)
  • 29 Nov 2022 Discontinued - Phase-I for Oesophageal cancer (In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in Netherlands, Taiwan, South Korea, Japan, Germany, France, Austria (Parenteral)
  • 02 Jun 2022 Amgen terminates phase I trial in Gastric cancer and Oesophageal cancer (In adults, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Taiwan, Netherlands, South Korea, Japan, Germany, France, Austria due to business decision (Parenteral) (NCT04260191)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top